The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $16.76 in the prior trading day, Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) closed at $17.85, up 6.50%. In other words, the price has increased by $6.50 from its previous closing price. On the day, 0.51 million shares were traded. ARCT stock price reached its highest trading level at $18.5 during the session, while it also had its lowest trading level at $17.0.
Ratios:
Our goal is to gain a better understanding of ARCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On May 28, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $32. On January 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $41.BTIG Research initiated its Buy rating on January 28, 2025, with a $41 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chivukula Pad sold 12,000 shares for $20.76 per share. The transaction valued at 249,121 led to the insider holds 435,334 shares of the business.
Chivukula Pad bought 12,000 shares of ARCT for $249,121 on Oct 15 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 484707840 and an Enterprise Value of 315205344. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.41 while its Price-to-Book (P/B) ratio in mrq is 2.10. Its current Enterprise Value per Revenue stands at 2.581 whereas that against EBITDA is -4.551.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.39, which has changed by -0.06052631 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $25.88, while it has fallen to a 52-week low of $8.04. The 50-Day Moving Average of the stock is 19.97%, while the 200-Day Moving Average is calculated to be 22.35%.
Shares Statistics:
The stock has traded on average 536.11K shares per day over the past 3-months and 432550 shares per day over the last 10 days, according to various share statistics. A total of 27.15M shares are outstanding, with a floating share count of 24.86M. Insiders hold about 8.44% of the company’s shares, while institutions hold 95.21% stake in the company. Shares short for ARCT as of 1755216000 were 5144057 with a Short Ratio of 9.60, compared to 1752537600 on 4481461. Therefore, it implies a Short% of Shares Outstanding of 5144057 and a Short% of Float of 29.29.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.12 and low estimates of -$1.88.
Analysts are recommending an EPS of between -$1.04 and -$4.42 for the fiscal current year, implying an average EPS of -$2.53. EPS for the following year is -$2.06, with 9.0 analysts recommending between $1.41 and -$4.78.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $116.18M, while the lowest revenue estimate was $57.68M, resulting in an average revenue estimate of $89.64M. In the same quarter a year ago, actual revenue was $152.31MBased on 11 analysts’ estimates, the company’s revenue will be $101.46M in the next fiscal year. The high estimate is $279.39M and the low estimate is $14.63M.
